Fecal calprotectin tests are stool-based diagnostic tests that detect and measure the levels of calprotectin in feces. Calprotectin is a protein released by the immune system during intestinal inflammation. It is widely used for screening and monitoring inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. The test aids in determining intestinal inflammation and distinguishing it from irritable bowel syndrome. It provides accurate, noninvasive means of testing for intestinal inflammation compared to endoscopy.

The global fecal calprotectin test market is estimated to be valued at US$ 140.6 Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
The rising incidences and prevalence of inflammatory bowel disease is a key factor driving the growth of the fecal calprotectin test market. It is estimated that the prevalence of IBD will increase from 3.1 million affected individuals in Europe and 2.0 million in North America and is projected to affect over 6.8 million individuals by 2050. Early detection of intestinal inflammation through noninvasive means is expected to aid clinical management of IBD and minimize invasive endoscopic procedures. This is increasing adoption of fecal calprotectin tests, thereby fueling market growth over the forecast period.

SWOT Analysis

Strength: The fecal calprotectin test market has strong growth potential owing to its ability to quantify gut inflammation. The test is non-invasive, easy-to-use, and provides objective and quantitative results for IBD diagnosis and monitoring. It delivers quick turnaround time and testing can be performed in clinics and hospitals, increasing convenience for patients.

Weakness: The high costs associated with fecal calprotectin tests limit their widespread adoption, especially in emerging markets. Sample collection and transportation challenges exist if testing is not available locally. Dependence on qualified laboratory technicians for analysis impacts scalability.

Opportunity: Growing geriatric population vulnerable to IBD and increasing awareness about fecal biomarkers for IBD diagnosis present major opportunities. Expanding applications of fecal calprotectin testing for other indications like intestinal infections, colorectal cancer screening can boost the market. Point-of-care testing devices promise to address existing weaknesses and facilitate adoption in new markets.

Threats: Stringent regulations for in vitro diagnostic devices pose compliance challenges. Presence of substitutes like fecal occult blood tests and presence of asymptomatic gut inflammation threaten market growth to some extent.

Key Takeaways

The global Fecal Calprotectin Test Market is expected to witness high growth over the forecast period of 2023 to 2030. The market size is estimated to reach US$ 140.6 Mn in 2023 and projected to grow at a CAGR of 10% during the forecast period.

Regional analysis: North America currently dominates the global market owing to robust healthcare infrastructure and high disease awareness. However, Asia Pacific region is expected witness the fastest growth on account of growing healthcare expenditure, rapidly aging population and increasing focus of key market players in emerging economies.

Key players: Key players operating in the fecal calprotectin test market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbexa Limited, Bioserv Diagnostics Gmbh, Epitope Diagnostics, Inc., LifeSpan BioSciences, Inc., RayBiotech, Inc., ALPCO. These companies focus on new product launches, geographical expansions and strategic collaborations to strengthen their market position.

 

Get more insights on this topic: https://www.timessquarereporter.com/business/growth-accelerated-by-rising-demand-for-noninvasive-diagnosis-of-inflammatory-bowel-disease